The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release

Published:2019-08 Issue:6 Volume:28 Page:1447-1454.e4
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Saponaro Chiara,Gmyr Valéry,Thévenet Julien,Moerman Ericka,Delalleau Nathalie,Pasquetti Gianni,Coddeville Anais,Quenon Audrey,Daoudi Mehdi,Hubert Thomas,Vantyghem Marie-Christine,Bousquet Corinne,Martineau Yvan,Kerr-Conte Julie,Staels Bart,Pattou François,Bonner Caroline

Funder

AstraZeneca

Conseil Régional Nord-Pas de Calais

Société Francophone du Diabète

European Commission

European Genomic Institute for Diabetes

European Consortium for Islet Transplantation

Juvenile Diabetes Research Foundation

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference54 articles.

1. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus;Abdul-Ghani;Am. J. Physiol. Renal Physiol.,2015

2. Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease;Anholm;Diabetol. Metab. Syndr.,2019

3. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial;Bailey;Lancet,2010

4. Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study);Bajaj;Diabetes Care,2017

5. Development of the insulin secretory defect in genetically diabetic (db/db) mouse;Berglund;Acta Endocrinol. (Copenh.),1978

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells;Peptides;2024-05

2. Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon‐like peptide 1;Clinical and Experimental Pharmacology and Physiology;2024-03-25

3. Somatostatin Containing δ-Cell Number Is Reduced in Type-2 Diabetes;International Journal of Molecular Sciences;2023-02-09

4. Where to for precision treatment of HNF1A-MODY?;Diabetologia;2022-04-12

5. High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination;Clinics and Practice;2021-12-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3